Gouvernance Immune Pharmaceuticals, Inc. OTC Markets

IMNPQ

US45254C2008

Produits pharmaceutiques

Temps Différé OTC Markets			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		-.--%	-23,08%

Comité Exécutif: Immune Pharmaceuticals, Inc.

Dirigeant

Fonctions occupéesDepuis

John Zhang

Chief Tech/Sci/R&D Officer

11/12/2017

John P. Clark

54 ans

Comptroller/Controller/Auditor	20/11/2017
Corporate Secretary	20/11/2017

Devin J. Shaw

39 ans

Director of Finance/CFO

13/04/2021

Composition du Conseil d'Administration: Immune Pharmaceuticals, Inc.

Administrateur

ComitésDepuis

David Sidransky

66 ans

Audit Committee	01/06/2014
Compensation Committee Chair	01/06/2014
Nominating Committee Chair	01/11/2017
Compensation Committee	01/11/2017
Governance Committee Chair	01/11/2017

Jeff Paley

57 ans

Audit Committee	23/02/2016
Compensation Committee	23/02/2016
Governance Committee Chair	23/02/2016
Nominating Committee Chair	23/02/2016

John A. Neczesny

62 ans

Audit Committee	02/02/2016
Compensation Committee	02/02/2016
Governance Committee	02/02/2016
Nominating Committee	02/02/2016

Tony Fiorino

58 ans

Director/Board Member

06/03/2019

Daniel Kazado

61 ans

Director/Board Member

19/10/2016

Anciens Dirigeants et Administrateurs: Immune Pharmaceuticals, Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Gary H. Rabin

Director/Board Member	06/03/2019	12/04/2021
Chief Executive Officer	06/03/2019	12/04/2021
President	06/03/2019	12/04/2021

Adeel Ahmed-Daudpota

Chief Executive Officer	12/04/2021	-
President	12/04/2021	-

Cameron Durrant

Director/Board Member	10/07/2014	10/09/2018
Independent Dir/Board Member	10/07/2014	10/09/2018

Elliot M. Maza

Comptroller/Controller/Auditor	21/11/2017	28/08/2018
Director/Board Member	14/01/2015	28/08/2018
Chief Executive Officer	01/09/2017	28/08/2018
Director of Finance/CFO	21/11/2017	28/08/2018
Independent Dir/Board Member	14/01/2015	-
Investor Relations Contact	14/01/2015	28/08/2018
President	01/12/2017	28/08/2018
Corporate Secretary	01/12/2017	28/08/2018

Daniel Teper

Director/Board Member	01/01/2010	01/05/2018
Chief Executive Officer	26/08/2013	24/04/2017
Chairman	26/08/2013	15/12/2014
Founder	01/01/2010	01/05/2018

John Militello

Comptroller/Controller/Auditor	01/04/2015	21/11/2017
Director of Finance/CFO	01/04/2015	21/11/2017

Ranch C. Kimball

Chairman

27/01/2017

09/02/2017

Monica Luchi

Chief Tech/Sci/R&D Officer

19/11/2015

02/01/2017

Gad Berdugo

Chief Administrative Officer	03/06/2014	31/12/2015
Director/Board Member	03/06/2014	22/01/2015
Director of Finance/CFO	03/06/2014	31/12/2015
Independent Dir/Board Member	03/06/2014	22/01/2015
Corporate Secretary	03/06/2014	31/12/2015

G. John Mohr

Corporate Officer/Principal

07/12/2015

René-Pierre Azria

Director/Board Member	17/04/2015	03/12/2015
Independent Dir/Board Member	17/04/2015	03/12/2015

Miri Ben-Ami

Corporate Officer/Principal

19/11/2015

Boris Shore

Chief Tech/Sci/R&D Officer

René Lerer

Director/Board Member	15/10/2013	17/04/2015
Independent Dir/Board Member	10/10/2013	17/04/2015

Paul Ira Nadler

Chief Tech/Sci/R&D Officer

09/02/2015

Ana Stancic

Director/Board Member	26/08/2013	14/01/2015
Independent Dir/Board Member	-	14/01/2015

Elliot Goldstein

Chief Tech/Sci/R&D Officer

02/04/2014

01/12/2014

Eugene Williams

Chief Operating Officer

02/04/2014

01/11/2014

Isaac Kobrin

Director/Board Member

26/08/2013

10/06/2014

Karin Hehenberger

Chief Tech/Sci/R&D Officer	06/06/2014	-
Public Communications Contact	06/06/2014	-

Bob Cook

Director/Board Member	01/08/2013	01/04/2014
Director of Finance/CFO	01/08/2013	01/04/2014

Stephane Allard

Chief Tech/Sci/R&D Officer

01/03/2007

11/03/2014

Hervé de Kergrohen

Director/Board Member

26/08/2013

15/10/2013

Pierre Albouy

Director/Board Member

26/08/2013

15/10/2013

Suzy Jones

Corporate Officer/Principal

Adam Foley-Comer

Chief Tech/Sci/R&D Officer

Anna Baran

Investor Relations Contact

Jean Kadouche

Founder

Serge Goldner

Director of Finance/CFO

Anna Baran-Djokovic

Investor Relations Contact

Kaouthar Lbiati

Corporate Officer/Principal

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	9
Femme	0

Dont comité exécutif

Homme	3
Femme	0

Dont Administrateurs

Homme	5
Femme	0

Immune Pharmaceuticals Inc. est une société biopharmaceutique en phase clinique. Elle est engagée dans le développement de nouveaux agents thérapeutiques ciblés dans les domaines de l'immunologie, de l'inflammation, de la dermatologie et de l'oncologie. Elle opère en acquérant, développant et commercialisant des produits pharmaceutiques sur ordonnance. Son principal produit est le bertilimumab, qui est un anti-eotaxin-1 entièrement humain, un régulateur de l'immuno-inflammation. La société développe NanoCyclo, qui est une formulation nano-encapsulée de cyclosporine-A pour le traitement de la dermatite atopique et du psoriasis. Le portefeuille oncologique de la société comprend Ceplene, une petite molécule ciblant le récepteur de l'histamine-2 pour surmonter l'immunosuppression dans la leucémie myéloïde aiguë et d'autres tumeurs malignes. Azixa et crolibulin sont des agents de perturbation vasculaire. NanomAbs est une plateforme technologique qui permet l'administration ciblée de chimiothérapies dans les cellules cancéreuses.

Employés

Secteur

Produits pharmaceutiques

Plus d'informations sur la société